Polyacrylamide hydrogel (Bulkamid®) for stress urinary incontinence in women: a systematic review of the literature

详细信息    查看全文

• 作者：Anushuya Devi Kasi ; Vasilios Pergialiotis…
• 关键词：Bulkamid ; Polyacrylamide hydrogel ; Stress urinary incontinence
• 刊名：International Urogynecology Journal
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：27
• 期：3
• 页码：367-375
• 全文大小：549 KB
• 参考文献：1.National Institute for Health and Care Excellence (2013) NICE guidelines [CG171]. Urinary incontinence: the management of urinary incontinence in women. http://​guidance.​nice.​org.​uk/​CG171
  2.Kirchin V, Page T, Keegan PE, Atiemo K, Cody JD, McClinton S (2012) Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev 2:CD003881. doi:10.​1002/​14651858.​CD003881.​pub3 PubMed
  3.Bianchi-Ferraro AM, Jarmy-DiBella ZI, de Aquino Castro R, Bortolini MA, Sartori MG, Girão MJ (2014) Randomized controlled trial comparing TVT-O and TVT-S for the treatment of stress urinary incontinence: 2-year results. Int Urogynecol J 25(10):1343–1348CrossRef PubMed
  4.Committee Opinion No. 603: Evaluation of uncomplicated stress urinary incontinence in women before surgical treatment (2014). Obstet Gynecol 123(6):1403–1407
  5.Ter Meulen PH, Berghmans LC, van Kerrebroeck PE (2003) Systematic review: efficacy of silicone microimplants (Macroplastique) therapy for stress urinary incontinence in adult women. Eur Urol 44(5):573–582
  6.Klarskov N, Lose G (2008) Urethral injection therapy: what is the mechanism of action? Neurourol Urodyn 27(8):789–792CrossRef PubMed
  7.Fatton B, Savary D, Velemir L (2009) Obstructive suburethral mass following injection of dextranomer/hyaluronic acid copolymer. Int J Gynaecol Obstet 104(1):73–74CrossRef PubMed
  8.Loisel C, Secco M, Rocher-Barrat A, Caremel R, Grise P (2008) Periurethral pseudocysts following urethral injections of Zuidex: review of the literature. Prog Urol 18(13):1038–1043CrossRef PubMed
  9.Madjar S, Sharma AK, Waltzer WC, Frischer Z, Secrest CL (2006) Periurethral mass formations following bulking agent injection for the treatment of urinary incontinence. J Urol 175(4):1408–1410CrossRef PubMed
  10.Kotb AF, Campeau L, Corcos J (2009) Urethral bulking agents: techniques and outcomes. Curr Urol Rep 10(5):396–400CrossRef PubMed
  11.Lose G, Mouritsen L, Nielsen JB (2006) A new bulking agent (polyacrylamide hydrogel) for treating stress urinary incontinence in women. BJU Int 98(1):100–104CrossRef PubMed
  12.Zarini E, Supino R, Pratesi G, Laccabue D, Tortoreto M, Scanziani E, Ghisleni G, Paltrinieri S, Tunesi G, Nava M (2004) Biocompatibility and tissue interactions of a new filler material for medical use. Plast Reconstr Surg 114(4):934–942CrossRef PubMed
  13.Bello G, Jackson IT, Keskin M, Kelly C, Dajani K, Studinger R, Kim EM, Lincoln D, Silberberg B, Lee A (2007) The use of polyacrylamide gel in soft-tissue augmentation: an experimental assessment. Plast Reconstr Surg 119(4):1326–1336CrossRef PubMed
  14.Christensen LH, Breiting VB, Aasted A, Jørgensen A, Kebuladze I (2003) Long-term effects of polyacrylamide hydrogel on human breast tissue. Plast Reconstr Surg 111(6):1883–1890CrossRef PubMed
  15.Christensen LH, Nielsen JB, Mouritsen L, Sørensen M, Lose G (2008) Tissue integration of polyacrylamide hydrogel: an experimental study of periurethral, perivesical, and mammary gland tissue in the pig. Dermatol Surg 34(Suppl 1):S68–S77, discussion S77PubMed
  16.Lose G, Sørensen HC, Axelsen SM, Falconer C, Lobodasch K, Safwat T (2010) An open multicenter study of polyacrylamide hydrogel (Bulkamid®) for female stress and mixed urinary incontinence. Int Urogynecol J 21(12):1471–1477PubMedCentral CrossRef PubMed
  17.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700PubMedCentral CrossRef PubMed
  18.Toozs-Hobson P, Al-Singary W, Fynes M, Tegerstedt G, Lose G (2012) Two-year follow-up of an open-label multicenter study of polyacrylamide hydrogel (Bulkamid®) for female stress and stress-predominant mixed incontinence. Int Urogynecol J 23(10):1373–1378PubMedCentral CrossRef PubMed
  19.Leone Roberti Maggiore U, Alessandri F, Medica M, Gabelli M, Venturini PL, Ferrero S (2013) Outpatient periurethral injections of polyacrylamide hydrogel for the treatment of female stress urinary incontinence: effectiveness and safety. Arch Gynecol Obstet 288(1):131–137CrossRef PubMed
  20.Martan A, Masata J, Svabik K, Krhut J (2014) Transurethral injection of polyacrylamide hydrogel (Bulkamid®) for the treatment of female stress or mixed urinary incontinence. Eur J Obstet Gynecol Reprod Biol 178:199–202CrossRef PubMed
  21.Trutnovsky G, Tamussino K, Greimel E, Bjelic-Radisic V (2011) Quality of life after periurethral injection with polyacrylamide hydrogel for stress urinary incontinence. Int Urogynecol J 22(3):353–356CrossRef PubMed
  22.Beraru A, Droupy S, Wagner L, Soustelle L, Muyschondt C, Ben Naoum K, Grés P, Boukaram M, Costa P (2014) Efficacy of periurethral injections of polyacrylamide hydrogel (Bulkamid®) and quality of life of patients with urinary incontinence due to sphincter deficiency (IUE-IS). Prog Urol 24(8):501–510CrossRef PubMed
  23.Sokol ER, Karram MM, Dmochowski R (2014) Efficacy and safety of polyacrylamide hydrogel for the treatment of female stress incontinence: a randomized, prospective, multicenter North American study. J Urol 192(3):843–849CrossRef PubMed
  24.Vecchioli-Scaldazza CV, Smaali C, Morosetti C, Azizi B, Giannubilo W, Ferrara V (2014) Polyacrylamide hydrogel (Bulkamid®) in female patients of 80 or more years with urinary incontinence. Int Braz J Urol 40(1):37–43PubMed
  25.Davis NF, Kheradmand F, Creagh T (2013) Injectable biomaterials for the treatment of stress urinary incontinence: their potential and pitfalls as urethral bulking agents. Int Urogynecol J 24(6):913–919CrossRef PubMed
  26.Martan A, Masata J, Svabik K, El-Haddad R, Hubka P (2011) Transurethral injection of polyacrylamide hydrogel (Bulkamid®) for the treatment of female stress urinary incontinence and changes in the cure rate over time. Ceska Gynekol 76(6):476–481PubMed
  27.Cloutier J, Blais AS, Moore K, Bolduc S (2013) Prospective study using a new bulking agent for the treatment of vesicoureteral reflux: polyacrylamide hydrogel. J Urol 190(3):1034–1037CrossRef PubMed
  28.Mohr S, Siegenthaler M, Mueller MD, Kuhn A (2013) Bulking agents: an analysis of 500 cases and review of the literature. Int Urogynecol J 24(2):241–247CrossRef PubMed
  29.Leone Roberti Maggiore U, Alessandri F, Medica M, Gabelli M, Venturini PL, Ferrero S (2012) Periurethral injection of polyacrylamide hydrogel for the treatment of stress urinary incontinence: the impact on female sexual function. J Sex Med 9(12):3255–3263CrossRef PubMed
  30.Gopinath D, Smith ARB, Reid FM (2012) Periurethral abscess following polyacrylamide hydrogel (Bulkamid®) for stress urinary incontinence. Int Urogynecol J 23:1645–1648CrossRef PubMed
  
• 作者单位：Anushuya Devi Kasi (1)
  Vasilios Pergialiotis (2)
  Despina N. Perrea (2)
  Azar Khunda (1)
  Stergios K. Doumouchtsis (1) (2)
  
  1. Department of Obstetrics and Gynaecology, Urogynaecology Unit, St. George’s University Hospitals NHS Foundation Trust, London, SW17 0QT, UK
  2. Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Medical School, University of Athens, Athens, Greece
  
• 刊物主题：Gynecology; Urology/Andrology;
• 出版者：Springer London
• ISSN：1433-3023

文摘

Introduction and hypothesis Polyacrylamide hydrogel (PAHG, Bulkamid®) is one of several injectable agents currently used for the treatment of women with urinary stress incontinence. Although bulking agents appear to have lower efficacy rates compared to other surgical treatments, current evidence based on large prospective or comparative studies as well as systematic reviews is limited. The purpose of this study was to conduct a systematic review on the efficacy of PAHG in the treatment of female patients with stress urinary incontinence with regard to reproducibility, feasibility, safety and clinical outcome.